|
See related Lucentis inj information |
|
|
|
Manufacturer |
Novartis |
|
Distributor |
Zuellig |
|
Contents |
Ranibizumab |
|
Indications |
Treatment of neovascular (wet) age-related macular degeneration.
Click to view Lucentis detailed prescribing infomation |
|
Dosage |
0.5 mg (0.05 mL) by intravitreal inj, initiated w/ a loading phase of 3 mthly inj followed by a maintenance phase. Interval between 2 doses should not be <1 mth.
Click to view Lucentis detailed prescribing infomation |
|
Overdosage |
View Lucentis overdosage for action to be taken in the event of an overdose. |
|
Contraindications |
Active or suspected ocular or periocular infections, active severe intraocular inflammation.
Click to view Lucentis detailed prescribing infomation |
|
Special Precautions |
Observe proper aseptic inj technique to avoid infection & inflammation. Monitor IOP & the perfusion of the optic nerve head. Risk of immunogenicity. May impair ability to drive or operate machinery. Pregnancy & lactation.
Click to view Lucentis detailed prescribing infomation |
|
Adverse Drug Reactions |
Conjunctival haemorrhage, eye pain, vitreous floaters, retinal haemorrhage, increased IOP, vitreous detachment, intraocular inflammation, eye irritation, cataract, foreign body sensation in eyes, increased lacrimation, eye pruritus, visual disturbance, blepharitis, subretinal fibrosis, ocular hyperaemia, maculopathy, blurred/decreased visual acuity, detachment of the retinal pigment epithelium, dry eye. Upper resp tract infection, nasopharyngitis, headache, HTN, nausea, constipation, arthralgia.
View ADR Monitoring Form |
|
Drug Interactions |
[Click for Lucentis detailed prescribing infomation]
View more drug interactions with Lucentis |
|
Pregnancy Category (US FDA) |
Category C: Either studies in animals have revealed adverse effects on the foetus (teratogenic or embryocidal or other) and there are no controlled studies in women or studies in women and animals are not available. Drugs should be given only if the potential benefit justifies the potential risk to the foetus. |
|
Storage |
View Lucentis storage conditions for details to ensure optimal shelf-life. |
|
Description |
View Lucentis description for details of the chemical structure and excipients (inactive components). |
|
Mechanism of Action |
View Lucentis mechanism of action for pharmacodynamics and pharmacokinetics details. |
|
Presentation/Packing |
|
Form |
Packing |
Photo |
|
Lucentis injection |
|
Lucentis 10 mg/1 mL x 0.23 mL x 1's |
 |
|
|
|
Manufacturer: |
Novartis |
|
Distributor: |
Zuellig |
|
|
|
|
